PMEF
AVIR icon

Point72 Middle East FZE’s Atea Pharmaceuticals AVIR Stock Holding History

Point72 Middle East FZE’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,148
Closed -$40.1K – 134
2023
Q4 		$40.1K Buy
13,148
+10,941
+496% +$33.1K ﹤0.01% 1307
2023
Q3 		$6.62K Sell
2,207
-6,375
-74% -$21.7K ﹤0.01% 1366
2023
Q2 		$32.1K Buy
+8,582
New +$32.1K ﹤0.01% 1342
2023
Q1 		– Sell
-2,287
Closed -$11K – 1638
2022
Q4 		$11K Buy
+2,287
New +$11.6K ﹤0.01% 1719

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Middle East FZE's AVIR Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Atea Pharmaceuticals (AVIR) in Q1 2024, closing a stake of 13,148 shares — an estimated $40.1K sold.

Point72 Middle East FZE first reported a position in AVIR in Q4 2022 and held it in 4 quarters. The position peaked at $40.1K in Q4 2023. 113 funds tracked by Wall St. Rank hold AVIR as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Atea Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 13,148 Atea Pharmaceuticals shares in Q1 2024, an estimated $40.1K.
  • Point72 Middle East FZE first reported a position in Atea Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Point72 Middle East FZE's Atea Pharmaceuticals position peaked at $40.1K in Q4 2023.
  • 113 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.